ELAVL4

Across TCGA pan-cancer cohorts, ELAVL4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ELAVL4 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ELAVL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ELAVL4 expression acts as an unfavorable survival marker, although some lineages such as SKCM and STAD show a favorable association.

THYM, SARC, and SKCM are the cancer types where ELAVL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
SARC	OS	Median	All	0.127	0.860	<.001	9	view →
SKCM	OS	Median	All	1.000	0.865	.011	7	view →
LUAD	OS	Median	II,III,IV	0.079	0.677	<.001	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.345	.048	4	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ELAVL4–THYM (OS)

Open the THYM breakdown →